BTdCPU

BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone (HY-14648) (Dex) -resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma[1][2].

Product Specifications

CAS Number

[1257423-87-2]

Product Name Alternative

BR-941

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Phosphatase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/btdcpu.html

Purity

99.03

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C2N=NSC2=C1)NC3=CC=C(C(Cl)=C3)Cl

Molecular Formula

C13H8Cl2N4OS

Molecular Weight

339.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Burwick N, et al. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res. 2017 Apr;55:23-32. |[2]Chen T, et al. Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol. 2011 Jul 17;7 (9) :610-6.